Martin Reck
机构: LungenClinic, Deutsches Zentrum für Lungenforschung
每年引用次数
引用次数
引用: 109,628
H-指数: 123
I10-指数 : 535
出版物: 1,454
[Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study].
E. Kaukel , J. Von Pawel , G. Koschel , B. Haering
Pneumologie 52 ( 10) 570 -573
19
1998
483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC
R.M. Jotte , A. Sandler , V. Papadimitrakopoulou , F. Cappuzzo
Annals of Oncology 27
2016
Incidence of brain metastases in patients treated with bevacizumab
W. Wick , S. Srock , M. Reck , F. Winkler
European Journal of Cancer 49
2
2013
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). [2011 ASCO poster]
R. Jotte , J. Von Pawel , P. Lorigan , M. Domine
ASCO
2011
PACIFIC-6: A phase II study of durvalumab after sequential chemoradiotherapy in patients with unresectable Stage III NSCLC
U. Emeribe , N. Trunova , A. Franks , F. Wurschmidt
2020
Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie
M. Kolditz , W. Windisch , K. F. Rabe , M. Lommatzsch
Pneumologie 75 ( 01) 19 -30
2021
OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
H. Borghaei , J.R. Brahmer , L.G. Paz-Ares , K.J. O'Byrne
Journal of Thoracic Oncology 16 ( 1)
2021
MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
H. Borghaei , F. Skoulidis , B. Besse , K. Goto
Journal of Thoracic Oncology 16 ( 1)
8
2021
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles d’un doublet de chimiothérapie à base de sels de platine (CT) vs 4 cycles de chimiothérapie en 1re ligne (1L) de traitement du cancer bronchique non à petites cellules (CBNPC) stade avancé : CheckMate 9LA (CM 9LA)
L.G. Paz-Ares , A. Scherpereel , T.E. Ciuleanu , D.P. Carbone
Revue des Maladies Respiratoires Actualités 13 ( 1) 123
2021
OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
L.G. Paz-Ares , J. Bennouna , A. Scherpereel , T.-E. Ciuleanu
Journal of Thoracic Oncology 16 ( 1)
2021
PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
I. Cicin , G. Otterson , P.F. Yumuk , M. Boyer
Journal of Thoracic Oncology 16 ( 3)
2021
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
B. Besse , D. Planchard , J.-C. Soria , J.-C. Soria
Annals of Oncology 32 ( 6) 698 -709
2021
OA02.03 Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
N. Frost , S.m. Keller , X. Quantin , S.K. Jabbour
Journal of Thoracic Oncology 16 ( 3)
2021
PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
A. Bearz , O. Caffo , A. Follador , R. Chiari
Journal of Thoracic Oncology 16 ( 3)
2021
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
S. Gadgeel , M.J. Hochmair , E.B. Garon , T. Kurata
Journal of Thoracic Oncology 16 ( 3)
1
2021
P75.04 Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
J. Krisam , F. Bozorgmehr , T. Muley , S. Agelaki
Journal of Thoracic Oncology 16 ( 3)
2021
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
M. Tagliaferri , V. Velcheti , A. Gupta , A.K. Ganti
Journal of Thoracic Oncology 16 ( 3)
2021
153P Real-world study of NSCLC with EGFR exon 20 insertions
J. Krisam , A. Tufman , M. Wermke , P. Christopoulos
Journal of Thoracic Oncology 16 ( 4)
2021
98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
L. Paz-Ares , J. Bennouna , A. Scherpereel , S. Agrawal
Journal of Thoracic Oncology 16 ( 4)
2021
118P The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small cell lung cancer
J. Krisam , T. Muley , E. Samantas , K. Syrigos
Journal of Thoracic Oncology 16 ( 4)
2021